CSL (CSLLY) Stock Forecast & Price Target

CSL
Bull Case

Here are some ways that investors could benefit from investing in CSL Limited:

• CSL Limited recently secured a significant supply deal with Haemonetics, a move that was highlighted by Bank of America, which upgraded Haemonetics to buy on the news, suggesting strong strategic partnerships and potential revenue growth for CSL Limited.
• The company received a positive rating upgrade from Royal Bank of Canada, which moved its stance from hold to moderate buy, indicating that institutional investors are increasingly confident in the long-term value proposition of CSL Limited.
• CSL Limited reported positive top-line Phase 3b results for ANDEMBRY in children with hereditary angioedema, supporting a planned expanded pediatric filing, which demonstrates strong pipeline progress and potential for market expansion in rare disease treatments.
• Short interest in CSL Limited has decreased significantly, dropping 32.7% in August to 219,694 shares, which suggests that fewer investors are betting against the stock and that market sentiment is improving.
• With a current stock price of $31.10, CSL Limited offers a dividend yield of 2.41%, providing a steady income stream for investors while the company continues to operate in the high-growth biotechnology sector.